by Maria Zannes | Feb 9, 2026 | Press Releases
Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath® Lung diagnostic test SAN ANTONIO, Texas – February 9, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology...
by Maria Zannes | Jan 7, 2026 | Press Releases
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets gold standard for excellence across all laboratory service lines CAP accreditation reaffirms CyPath® Lung test’s...
by Maria Zannes | Dec 3, 2025 | Press Releases
SAN ANTONIO, Texas – December 3, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will...
by Maria Zannes | Dec 2, 2025 | Publications
American Cancer Society National Lung Cancer Roundtable, December 7, 2025 Author: Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer. Three patient case studies in which CyPath® Lung, a noninvasive sputum-based flow cytometry test,...
by Maria Zannes | Nov 14, 2025 | Press Releases
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO, Texas – November 14, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of...
